Pseudoxanthoma Elasticum Clinical Trial
Official title:
A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults With ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) recombinant fusion protein, for the treatment of ABCC6 Deficiency. The goal of the study is to identify a dose regimen for further clinical development in the treatment of ABCC6 Deficiency.
INZ-701 is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) recombinant fusion protein in development for the treatment of ABCC6 Deficiency, a rare genetic disorder. Study INZ701-201 is a Phase 1/2, multicenter, open-label, multiple ascending dose (MAD), dose-finding study followed by a long-term open-label Extension Period conducted in adults with ABCC6 Deficiency manifesting as Pseudoxanthoma elasticum (PXE). This study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-701. The goal of the study is to identify a dose and dose schedule (number of doses per week) for further clinical development. Exploratory endpoints for the Extension Period of the study include evaluations of arterial and organ calcification, ophthalmologic, cardiac and renal parameters, and physical function as well as patient reported outcomes. Subject participation consists of a Screening Period of up to 60 days, a 32-day Dose Evaluation Period, and an Extension Period during which subjects may continue to receive INZ-701 (with options for self-, caregiver-, or healthcare provider administration) until INZ-701 is approved and available in the country where the subject resides or until an alternative study for subjects to continue receiving study drug is available. During the Extension Period, follow-up visits will be conducted every 4 weeks until Week 48, followed by every 12 weeks until the subject leaves the study. Subjects will complete a follow up visit 30 days after their last dose of INZ-701. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02537054 -
Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)
|
Phase 2 | |
Active, not recruiting |
NCT05569252 -
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
|
Phase 2 | |
Recruiting |
NCT05662085 -
Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
|
||
Completed |
NCT03070860 -
What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum
|
N/A | |
Completed |
NCT01446393 -
Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE)
|
N/A | |
Completed |
NCT00470977 -
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT03758534 -
Natural History of GACI With or Without ARHR2 or PXE
|
||
Recruiting |
NCT01446380 -
Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort
|
N/A | |
Recruiting |
NCT03813550 -
Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)
|
N/A | |
Not yet recruiting |
NCT03364504 -
Biological Collection of Kidney Cells
|
N/A | |
Active, not recruiting |
NCT02108392 -
Characterization of Pseudoxanthoma Elasticum
|
||
Recruiting |
NCT01731080 -
Arterial Wall Calcium Load in Pseudoxanthoma Elasticum
|
N/A | |
Completed |
NCT00555113 -
Evolution of Visual Impairment During Pseudoxanthoma Elasticum
|
N/A | |
Completed |
NCT00341419 -
Genetic Analysis of Patients With Pseudoxanthoma Elasticum
|
||
Withdrawn |
NCT04441671 -
Oral Pyrophosphate Absorption in PXE Disease
|
Phase 2 | |
Recruiting |
NCT04868578 -
PPI Supplementation to Fight ECtopIc Calcification in PXE
|
N/A | |
Completed |
NCT05025722 -
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
|
||
Completed |
NCT01525875 -
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
|
Phase 2 | |
Completed |
NCT05246189 -
Employment of Patients With Pseudoxanthoma Elasticum
|
||
Recruiting |
NCT05832580 -
The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum
|
Phase 3 |